Drug Type Oncolytic virus |
Synonyms OH2 Oncolytic Viral Therapy, rHSV2hGM-CSF + [5] |
Target |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 3 | CN | 23 Feb 2023 | |
Colorectal Liver Metastases | Phase 2 | CN | 20 Oct 2022 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 2 | CN | 11 Jul 2022 | |
Bladder Cancer | Phase 2 | CN | 25 May 2022 | |
Locally Advanced Bladder Carcinoma | Phase 2 | CN | 23 May 2022 | |
Metastatic Neoplasm to the Bladder | Phase 2 | CN | 23 May 2022 | |
Central Nervous System Neoplasms | Phase 2 | CN | 16 Nov 2021 | |
Advanced Colorectal Adenocarcinoma | Preclinical | CN | 17 Oct 2023 | |
Colorectal Cancer | Preclinical | CN | 17 Oct 2023 | |
Pancreatic Cancer | Preclinical | CN | 02 Feb 2021 |
Phase 1 | - | (uderzwhatr) = fkttcdgyiq pnlntjagkl (vzsieypcmm ) | Positive | 06 Nov 2022 | |||
(接受PD-1治疗失败且疾病分期为III-IVM1a的亚组人群) | (uderzwhatr) = mvfafzesws pnlntjagkl (vzsieypcmm ) | ||||||
NCT04386967 (ASCO2022) Manual | Phase 1 | 35 | (ymfzmijwtk) = xipkuykowp lsthyrsdvi (cgwrrppatq ) View more | Positive | 02 Jun 2022 |